Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:04 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
10,836,936 | 9,773,241 | 9,807,100 | 9,456,633 | 10,377,453 |
Cost of Goods Sold (COGS) incl. D&A |
4,106,410 | 3,671,078 | 3,670,305 | 3,739,921 | 3,770,875 |
COGS excluding D&A |
3,517,633 | 2,911,350 | 2,978,870 | 2,996,654 | 3,122,446 |
Depreciation & Amortization Expense |
588,777 | 759,728 | 691,435 | 743,267 | 648,429 |
Gross Income |
6,730,526 | 6,102,163 | 6,136,795 | 5,716,712 | 6,606,578 |
SG&A Expense |
4,334,203 | 3,817,110 | 3,955,374 | 4,005,990 | 4,006,110 |
Research & Development |
1,141,431 | 1,022,187 | 1,010,882 | 1,005,682 | 1,100,607 |
Other SG&A |
3,192,772 | 2,794,923 | 2,944,492 | 3,000,308 | 2,905,503 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
1,450,973 | 207,000 | -117,000 | 161,000 | 554,000 |
Non Operating Income/Expense |
-7,223 | 6,110 | -95,374 | 62,736 | -8,473 |
Interest Expense |
87,312 | 230,034 | 220,191 | 116,866 | 108,086 |
Gross Interest Expense |
88,312 | 236,034 | 220,191 | 116,866 | 108,086 |
Pretax Income |
873,887 | 1,872,384 | 2,003,317 | 1,513,029 | 1,953,705 |
Income Tax |
-179,494 | -70,422 | 278,705 | 270,905 | 335,037 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
1,053,381 | 1,942,806 | 1,724,612 | 1,242,124 | 1,618,668 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
1,053,381 | 1,942,806 | 1,724,612 | 1,242,124 | 1,618,668 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
1,053,380 | 1,942,806 | 1,724,611 | 1,242,124 | 1,618,668 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
1,053,381 | 1,942,806 | 1,724,612 | 1,242,124 | 1,618,668 |
Operational EPS |
1.30 | 1.31 | 1.03 | 0.85 | 1.26 |
EPS (basic) |
0.67 | 1.22 | 1.09 | 0.79 | 1.03 |
EBITDA |
2,985,100 | 3,044,781 | 2,872,856 | 2,453,989 | 3,248,897 |
Depreciation & Amortization Expense |
588,777 | 759,728 | 691,435 | 743,267 | 648,429 |
Common Shares Outstanding |
1,591,838 | 1,594,279 | 1,588,502 | 1,589,510 | 1,586,929 |
Basic Shares Outstanding |
1,575,378 | 1,576,771 | 1,572,099 | 1,573,921 | 1,571,522 |
Diluted Shares Outstanding |
1,591,838 | 1,594,279 | 1,588,502 | 1,589,510 | 1,586,929 |
Diluted EPS after Extraordinary Items |
0.66 | 1.22 | 1.09 | 0.78 | 1.02 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.67 | 1.23 | 1.10 | 0.79 | 1.03 |
*Figures in thousands of U.S. Dollars except shares outstanding.
